Mirum Pharma (MIRM) Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool

Wed, April 1, 2026 astatine 8:53 AM CDT 23 min read

Image source: The Motley Fool.

Tuesday, Nov. 4, 2025 astatine 8 a.m. ET

• Chief Executive Officer — Christopher Peetz

• President and Chief Operating Officer — Peter Radovich

• Chief Medical Officer — Joanne M. Quan

• Chief Financial Officer — Eric Bjerkholt

Need a punctuation from a Motley Fool analyst? Email [email protected]

Christopher Peetz: Thanks, Andrew, and bully afternoon, everyone. 2025 continues to beryllium an outstanding twelvemonth for Mirum. We've created a starring uncommon illness company, purpose-built to make and present life-changing medicines to patients. Our occurrence comes from that foundation. The squad profoundly connected to patients and families, turning their insights into meaningful therapies and measurable performance. In the 3rd quarter, we delivered beardown commercialized results, precocious our objective pipeline and strengthened our fiscal foundation. I'm arrogant of the mode our squad continues to execute with absorption and consistency. First, connected commercialized performance. We reported 3rd 4th gross of $133 million, representing a astir 50% year-over-year summation implicit the aforesaid play past year.

This show reflects the spot and breadth of our commercialized portfolio, including continued momentum from the U.S. PFIC motorboat and expanding request from our planetary markets. Turning to R&D. We stay connected way for 3 perchance pivotal readouts implicit the adjacent 18 months. First up is the VISTAS Phase IIb survey successful PSC. With enrollment complete, we expect to denote apical enactment information successful the 2nd 4th of 2026. With the palmy interim investigation past twelvemonth and a accordant assemblage of supporting information with IBAT inhibitors crossed aggregate cholestatic diseases, we're optimistic astir volixibat's imaginable to go the archetypal approved attraction successful this setting.

We are besides progressing good with our VANTAGE survey of volixibat successful PBC, the EXPAND survey of LIVMARLI successful ultra-rare cholestatic conditions, and our recently initiated Phase II survey of MRM-3379 successful Fragile X syndrome. We've besides taken meaningful steps to further fortify our fiscal performance. This quarter, our currency equilibrium grew significantly, and we recognized affirmative nett income for the archetypal time. This is an important milestone that highlights the operating leverage successful our commercialized model. In sum, it's been different coagulated 4th of execution for Mirum. I privation to convey the full Mirum squad for their continued dedication to patients.

We built a high-growth currency flow-positive uncommon illness institution with a wide pipeline and planetary footprint, and we're conscionable getting started. And with that, I'll manus the telephone implicit to Peter. Peter?